Edit
Maxion Therapeutics, Limited.
https://www.maxiontherapeutics.com/Last activity: 06.12.2025
Active
Maxion Therapeutics is a biotechnology company that uses its revolutionary KnotBody® technology to create first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases. They have a mission to develop innovative therapies that improve the lives of patients suffering from chronic pain.
Location: United Kingdom, England, South Hams
Total raised: $93.79M
Investors 4
| Date | Name | Website |
| 06.12.2025 | AJU IB Inv... | ajuib.co.k... |
| 10.03.2023 | BGF Ventur... | bgf.co.uk |
| - | Life Arc V... | lifearcven... |
| 06.05.2025 | Solasta Ve... | solasta-ve... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 18.03.2025 | Series A | $75.31M | - |
| 19.04.2023 | - | $2.48M | - |
| 19.02.2023 | Series A | $16M | - |
Mentions in press and media 18
| Date | Title | Description |
| 06.10.2025 | NanoPhoria closes €83.5 million Series A for its heart failure candidate – one of Italy’s largest 2025 BioTech rounds | Milan-based NanoPhoria Bioscience today announced the successful first close of its €83.5 million Series A financing round – the largest ever Series A round in Italian BioTech history – for its lung-to-heart drug delivery platform. The roun... |
| 19.09.2025 | Startup Funding: Luke Rajah, BGF Early Stage Partner, Deep Tech and Life Sciences Luke Rajah is a Partner at BGF, focused on early-stage investments in deep tech and life sciences — two sectors where ... | From pioneering medtech breakthroughs to next-generation semiconductors, Rajah works closely with ambitious founders tackling some of the world's toughest challenges. In this Entrepreneur UK interview, he shares practical insights for early... |
| 22.03.2025 | European Tech Landscape: A Surge of Innovation and Investment | The European tech scene is buzzing. Funding rounds are breaking records. Startups are emerging like wildflowers after a spring rain. This week alone, over 75 tech funding deals were reported, totaling more than €865 million. The landscape i... |
| 22.03.2025 | European Tech Ecosystem: A Surge of Investment and Innovation | The European tech landscape is buzzing. Funding deals are sprouting like wildflowers after a spring rain. This week alone, over 75 tech funding deals were recorded, totaling more than €865 million. The momentum is palpable. Investors are fl... |
| 21.03.2025 | Factorial snaps up $120M, call for EU sovereign infrastructure fund, and startup-friendly Latvia | This week we tracked more than 75 tech funding deals worth over €865 million, and over 10 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most i... |
| 18.03.2025 | Maxion Therapeutics: A New Dawn in Biotech Innovation | In the heart of Cambridge, a biotech revolution is brewing. Maxion Therapeutics has just secured €68.9 million in a Series A funding round, marking a significant milestone in the quest for innovative therapies. This funding, led by General ... |
| 18.03.2025 | Maxion Therapeutics: £58 Million (Series A) Closed For Developing KnotBody Drugs For Ion Channel- And GPCR-Driven Diseases | Maxion Therapeutics, a biotechnology company developing antibody-based KnotBody drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, announced that it has raised $72 million (£58 million) in a Series A financing. Th... |
| 17.03.2025 | Maxion Therapeutics Raises $72M in Series A Funding | Maxion Therapeutics, a Cambridge, UK-based biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, raised $72M (£58M) in Series A funding. The round was led by ... |
| 17.03.2025 | Maxion Therapeutics raises €68 million to advance its KnotBody pipeline and platform | Cambridge-based Maxion Therapeutics, a BioTech company developing antibody-based KnotBody drugs for ion channel and G protein coupled receptor (GPCR) driven diseases, announced today that it has raised €68.9 million in a Series A financing.... |
| 17.03.2025 | Biotech Maxion Therapeutics secures $72M Series A | Cambridge-based Maxion Therapeutics, a biotech developing antibody-based drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, has raised $72M in a Series A round. The round was led by General Catalyst with additiona... |
Show more